Lifesci Capital Has Negative Outlook of Immunome Q3 Earnings

Immunome, Inc. (NASDAQ:IMNM) – Equities researchers at Lifesci Capital decreased their Q3 2026 earnings per share estimates for shares of Immunome in a report released on Monday, December 15th. Lifesci Capital analyst C. Zhu now forecasts that the company will post earnings of ($0.59) per share for the quarter, down from their previous forecast of ($0.55). The consensus estimate for Immunome’s current full-year earnings is ($2.21) per share. Lifesci Capital also issued estimates for Immunome’s Q4 2026 earnings at ($0.57) EPS and FY2026 earnings at ($2.44) EPS.

Immunome (NASDAQ:IMNM) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.08). Immunome had a negative net margin of 1,687.08% and a negative return on equity of 76.50%.

Several other brokerages also recently commented on IMNM. Evercore ISI increased their target price on Immunome from $18.00 to $40.00 and gave the company an “outperform” rating in a research note on Tuesday. Wall Street Zen raised Immunome from a “sell” rating to a “hold” rating in a report on Saturday, November 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunome in a report on Wednesday, October 8th. Stephens upped their target price on shares of Immunome from $25.00 to $33.00 and gave the company an “overweight” rating in a research note on Monday, November 17th. Finally, Truist Financial started coverage on shares of Immunome in a research note on Monday, December 1st. They issued a “buy” rating and a $36.00 price target for the company. Ten equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $30.09.

Immunome Stock Down 15.8%

NASDAQ:IMNM opened at $19.78 on Thursday. The stock has a market cap of $1.81 billion, a price-to-earnings ratio of -6.71 and a beta of 2.17. The company’s 50 day moving average price is $17.42 and its 200-day moving average price is $12.55. Immunome has a 52 week low of $5.15 and a 52 week high of $25.30.

Institutional Investors Weigh In On Immunome

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Assetmark Inc. bought a new position in shares of Immunome in the 3rd quarter worth approximately $39,000. BNP Paribas Financial Markets increased its holdings in Immunome by 81.8% during the second quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock valued at $60,000 after buying an additional 2,909 shares during the last quarter. Tower Research Capital LLC TRC raised its position in Immunome by 121.2% in the second quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company’s stock worth $65,000 after acquiring an additional 3,802 shares during the period. BIT Capital GmbH purchased a new position in shares of Immunome during the 3rd quarter worth $69,000. Finally, Russell Investments Group Ltd. bought a new stake in shares of Immunome during the 3rd quarter valued at $76,000. Hedge funds and other institutional investors own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.